<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474212</url>
  </required_header>
  <id_info>
    <org_study_id>290115-1</org_study_id>
    <nct_id>NCT02474212</nct_id>
  </id_info>
  <brief_title>: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery</brief_title>
  <official_title>Anti-Xa Concentrations With Continuous Intravenous Infusion and Subcutaneous Administration of Enoxaparin After Coronary Artery Bypass Grafting: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of thromboprophylactic doses of LMWH enoxaparin in&#xD;
      postoperative CABG patients, drug is administered either as a continuous intravenous infusion&#xD;
      (CIV) or subcutaneous bolus (SCB) once per 72h. Plasma anti-Xa values are measured 12-14&#xD;
      times during study period and concentration maximums calculated to enable comparison of&#xD;
      anti-Xa values between administration routes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, controlled trial. After informed consent, 80 elective on&#xD;
      pump CABG patients with a clinical indication for post-operative thromboprophylaxis will be&#xD;
      studied in the Tampere University Heart Hospital. Study has two independent parts with 40&#xD;
      patients in both. Results are reported separately from these two parts of the study.&#xD;
&#xD;
      Firts part of the study: After written consent, 20+20 patients are randomized to receive&#xD;
      enoxaparin either as continuous intravenous infusion (treatment group) or subcutaneous bolus&#xD;
      injection (control group). Enoxaparin dose is 40mg/24h either CIV of SCB. Anti-Xa values are&#xD;
      measured 12-14 times from blood samples to evaluate the anticoagulation effect of enoxaparin.&#xD;
&#xD;
      Second part of the study: After written consent, 20+20 patients are randomized to receive&#xD;
      enoxaparin either as continuous intravenous infusion (treatment group) or subcutaneous bolus&#xD;
      injection (control group). Enoxaparin dose is 1mg/kg/24h in CIV group and 0,5mg/kg twice a&#xD;
      day in SCB group. In this second part of the study with eleveted enoxaparin dosage, 4&#xD;
      additional blood samples will be taken and analysed by ROTEM to investigate the overall&#xD;
      coagulation status of the patients before and after the initiation of enoxaparin.&#xD;
&#xD;
      The study will consist of two independent parts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Xa concentration maximum 0-24h (Cmax0-24h)</measure>
    <time_frame>0-24h after initiation of enoxaparin</time_frame>
    <description>Anti-Xa concentration maximum level calculated from measured values during 0-24h after initiation of enoxaparin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Xa concentration maximum 25-72 h (Cmax25-72h)</measure>
    <time_frame>25-72 h after initiation of enoxaparin</time_frame>
    <description>Anti-Xa concentration maximum level calculated from measured values 25-72h after the initiation of enoxaparin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Xa trough concentartion at 72 h (C72h)</measure>
    <time_frame>72 h after the initiation of enoxaparin</time_frame>
    <description>Anti-Xa concentration at the of 72h study period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical outcomes</measure>
    <time_frame>0-90 days after initiation of enoxaparin</time_frame>
    <description>Postoperative bleeding, DVT, pulmonary embolism, 90 day mortality</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Thromboprophylaxis</condition>
  <arm_group>
    <arm_group_label>Enoxaparin 40 mg s.c.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 40 mg i.v.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 0.5 mg/kg s.c.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 1 mg/kg i.v.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>Enoxaparin 0.5 mg/kg s.c.</arm_group_label>
    <arm_group_label>Enoxaparin 1 mg/kg i.v.</arm_group_label>
    <arm_group_label>Enoxaparin 40 mg i.v.</arm_group_label>
    <arm_group_label>Enoxaparin 40 mg s.c.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI between 18-33 kg/m2&#xD;
&#xD;
          -  Elective on-pump CABG operation&#xD;
&#xD;
          -  Indication for post-operative pharmacological thromboprophylaxis&#xD;
&#xD;
          -  Written informed consent obtained from the patient or his/her legal representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other indications for anticoagulant therapy than thromboprophylaxis&#xD;
&#xD;
          -  Known heparin induced thrombocytopenia (HIT), or hypersensitivity to enoxaparin or&#xD;
             heparin&#xD;
&#xD;
          -  Any long-term anticoagulant medication, expect low-dose aspirin&#xD;
&#xD;
          -  Major bleeding within the last week unless definitively treated&#xD;
&#xD;
          -  Blood platelet count &lt;20, P-TT &lt;20 % or INR &gt;1.7&#xD;
&#xD;
          -  GFR less than 30 ml/min/1.73 m2 estimated from serum creatinine by applying&#xD;
             Cockcroft-Gault equation 13 or chronic dialysis&#xD;
&#xD;
          -  Known HIV, HBV, or HCV infection&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kati Järvelä, PhD</last_name>
    <phone>+358331164869</phone>
    <email>kati.jarvela@sydansairaala.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Parviainen, MD</last_name>
    <email>maria.parviainen@tuni.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Parviainen, MD</last_name>
      <phone>+358331166095</phone>
      <email>maria.parviainen@sydansairaala.fi</email>
    </contact>
    <contact_backup>
      <last_name>Kati Järvelä, PhD</last_name>
      <phone>+358331164869</phone>
      <email>kati.jarvela@sydansairaala.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Annukka Vahtera, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kati Järvelä, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juha Hautalahti, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Parviainen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>thromboprophylaxis</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>anti-FXa</keyword>
  <keyword>low-molecular weight heparin</keyword>
  <keyword>enoxaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

